Summary:
American Institute of Research is conducting a Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects with Non Muscle-
Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette-Guérin (BCG)
Participants must:
- Histologically-confirmed non muscle-invasive urothelial carcinoma (transitional cell carcinoma) of the bladder as follows:
- CIS (with or without papillary disease) OR
- Any grade T1 papillary disease OR
- High-grade Ta papillary disease
- have received adequate BCG treatment defined as at least 2 courses of BCG
- disease is refractory or has relapsed following adequate BCG treatment
Qualified Participants May Receive:
Free medical care and treatment as well as $50.00 for each completed visit.